Jasper Therapeutics jumps as asthma drug shows early promise

Jasper Therapeutics

02/12/2025 12:17

** Shares of drug developer Jasper Therapeutics JSPR.O  rise 17% to $2.02 in premarket trading

** Co says early-stage study of its experimental drug briquilimab improved lung function and reduced airway inflammation in allergic asthma patients

** Early-stage study enrolled about 17 patients in Canada; drug was well-tolerated with no serious safety issues - JSPR

** Co's briquilimab targets mast cells, which trigger asthma symptoms and allergic reactions - JSPR

** Up to last close, stock down ~92% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))